Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02244827 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment
A Phase 1 study, sponsored by Wockhardt.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02244827 is a Phase 1 study that has completed, run by Wockhardt. The registered enrollment target is 48 participants.
The verdict
NCT02244827, a Phase 1 study, has completed, sponsored by Wockhardt.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study is aimed to compare the pharmacokinetics of levonadifloxacin and its sulfate metabolite after a single dose of oral WCK 2349 1000 mg in patients with hepatic impairment and healthy volunteers.
Interventions
- DRUG WCK 2349
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02244827
The ClinicalTrials.gov registry entry for NCT02244827 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wockhardt, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WCK 2349 is the first listed.
NCT02244827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02244827 about?
NCT02244827 is a clinical study titled "Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment". This study is aimed to compare the pharmacokinetics of levonadifloxacin and its sulfate metabolite after a single dose of oral WCK 2349 1000 mg in patients with hepatic impairment and healthy volunteers.
What is the current status of trial NCT02244827?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2014-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02244827?
The interventions under investigation include: WCK 2349 (DRUG).
Who is sponsoring clinical trial NCT02244827?
This trial is sponsored by Wockhardt, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.